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ABSTRACT 
Extensive research into the therapeutics of asthma has yielded numerous effective 
interventions over the past few decades. However, adverse effects and ineffectiveness of most 
of these medications especially in the management of steroid resistant severe asthma 
necessitate the development of better medications. Numerous drug targets with inherent 
airway smooth muscle tone modulatory role have been identified for asthma therapy. This 
article reviews the latest understanding of underlying molecular aetiology of asthma towards 
design and development of better antiasthma drugs. New drug candidates with their putative 
targets that have shown promising results in the preclinical and/or clinical trials are 
summarised. Examples of these interventions include restoration of Th1/Th2 balance by the 
use of newly developed immunomodulators such as toll-like receptor-9 activators (CYT003-
QbG10 and QAX-935). Clinical trials revealed the safety and effectiveness of 
chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonists 
such as OC0000459, BI-671800 and ARRY-502 in the restoration of Th1/Th2 balance. 
Regulation of cytokine activity by the use of newly developed biologics such as 
benralizumab, reslizumab, mepolizumab, lebrikizumab, tralokinumab, dupilumab and 
brodalumab are at the stage of clinical development. Transcription factors are potential 
targets for asthma therapy, for example SB010, a GATA-3 DNAzyme is at its early stage of 
clinical trial. Other candidates such as inhibitors of Rho kinases (Fasudil and Y-27632), 
phosphodiesterase inhibitors (GSK256066, CHF 6001, roflumilast, RPL 554) and proteinase 
of activated receptor-2 (ENMD-1068) are also discussed. Preclinical results of blockade of 
calcium sensing receptor by the use of calcilytics such as calcitriol abrogates cardinal signs of 
asthma. Nevertheless, successful translation of promising preclinical data into clinically 
viable interventions remains a major challenge to the development of novel anti-asthmatics. 
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